Deep letter biological——Biocon Awards "Top 10 Innovative Companies with Investment Value for 2020"

Deep Biotech's LNP delivery technology platform, which has the confidence in its own intellectual property rights, has designed and constructed a lipid library with extremely diverse structures. It is one of the few companies globally that possess core lipid library design technology. In the face of different application scenarios, the company analyzes and optimizes synthesized LNP structures and activity data. Through multiple rounds of in vivo experiments, including multi-dimensional evaluations such as delivery efficiency, tissue distribution, and safety, it screens out Best-in-Class LNP structures that can meet specific needs. The company has now constructed a lipid library containing more than 5,000 types of ionizable lipids, which can be applied to the development of various innovative therapies, including mRNA vaccines and drugs, in vivo gene editing, and in vivo cell therapy.

In terms of mRNA technology, Shenxin Biotech is committed to finding the optimal sequences that can bind with ribosomes through rational design and optimization of sequences, in order to translate proteins more efficiently and sustainably. It also possesses proprietary patented technologies for mRNA sequence optimization, design of non-coding region vectors, etc. Moreover, it has patented technologies and 'know-how' capabilities in the development of CMC processes, as well as the production and supply capabilities for GMP-level lipid and mRNA-LNP formulation samples.

Delivery technology is a 'bottleneck' in the field of nucleic acid drugs and is crucial for the development of these medications. After years of accumulation, some overseas companies that were early to invest in nucleic acid delivery have formed a tight patent layout and erected high patent barriers, posing significant limitations and challenges to newcomers. Shenzhen Xincun Biotech focuses on the research and development of innovative delivery technologies, has built a global LNP delivery technology platform with independent intellectual property rights, and has applied for more than 40 related invention patents. The technology platform is continuously updated and iterated, and it has grown into one of the few companies in the world that possess the underlying innovation capabilities in LNP delivery technology. With its strong R&D strength and key technological breakthroughs, Shenzhen Xincun Biotech has successfully broken the monopoly of international giants over LNP delivery technology. It has currently developed new structural LNP carriers for various application scenarios such as infectious disease vaccines, tumor vaccines, immune cell delivery, liver delivery, spleen delivery, lung delivery, and eye delivery, laying a solid technical foundation for subsequent mRNA research and development work.

Deep Biotech is confident that by independently developing innovative mRNA vaccines and drugs, it continues to expand the boundaries of mRNA applications and clinical translation. Currently, the company has more than a dozen research and development pipelines, covering mRNA infectious disease vaccines, mRNA rare disease therapies, and mRNA tumor immunotherapy, all designed to address unmet clinical needs of patients worldwide. Most products in the R&D pipeline plan to undergo international multi-center clinical trials and global filings, among which three products have already obtained IND approvals from the US FDA and entered clinical trials.

On the other hand, Shenzhen Xinfeng Biotech is confident that relying on the advantages of the mRNA-LNP technology platform, it has reached cooperation agreements with multiple biopharmaceutical companies at home and abroad, including ZhiFei Biotech and BeiGene, through joint development or licensing. The business model of external cooperation not only injects self-sustaining capabilities into the company but also enables the company to continuously expand and improve its technology platform during the cooperation process, enhancing the overall strength of the team and thereby feeding back into the development of internal pipelines, forming a virtuous cycle. In 2023, Shenzhen Xinfeng Biotech reached an LNP platform licensing agreement with a globally renowned multinational enterprise, marking the first time in China that an LNP technology platform has gone global. This is not only a validation of Shenzhen Xinfeng Biotech's internationalization and innovation capabilities but also promotes the technological development of China's nucleic acid drug industry, enabling China's nucleic acid delivery technology to gain a foothold on the international stage.

Dr. Li Linxian, founder of Shenzhen InnoCell Biotech, once studied under Professor Robert Langer, a global top scholar in the mRNA field and founder of Moderna Technology. He founded Shenzhen InnoCell Biotech at the end of 2019. Over the years, the company has focused on the development of mRNA drugs and LNP delivery technologies, achieving several major scientific research results in the mRNA field and its "bottleneck" delivery technology. Dr. Li Linxian has received honors such as being named one of the "35 Under 35 Technological Innovators" by MIT Technology Review in 2017, one of the "40 Under 40 Business Elite" by Fortune China in 2023, and an In Vivo 'Rising Leaders' award in 2024. Currently, Shenzhen InnoCell Biotech has established a team, technology, and management system from early research and development to clinical development. The management team includes several senior executives with many years of experience in well-known pharmaceutical companies such as AstraZeneca, Johnson & Johnson, Roche, BMS, and Moderna. In addition, the company has set up 5 R&D and production centers in Shenzhen, Hong Kong, and Nanjing, possessing the full-process end-to-end development capabilities for mRNA drugs to support the product development of itself and its partners.